Loading...
21 companies we cover, 19 of them graded
Every company here put through the same five checks on growth and cash generation. It describes the industry as it reports today — not which of these to buy.
| LLY | ELI LILLY AND COMPANY | A+ | $1.11T | $1,183.46 | 39.71 | $79.7B | 33.5% |
| JNJ | Johnson & Johnson | A+ | $653.6B | $271.22 | 31.46 | $97.9B | 21.5% |
| ABBV | AbbVie Inc. | B | $467.1B | $264.34 | 74.67 | $64.4B | 9.8% |
| MRK | Merck & Co., Inc. | A | $367.1B | $148.78 | 118.08 | $66.6B | 4.8% |
| NVS | Novartis AG | A+ | $277.6B | $145.46 | 20.34 | $56.7B | 24.7% |
| AZN | ASTRAZENECA PLC | A+ | $260.2B | $166.58 | 25.47 | $58.7B | 17.4% |
| AMGN | Amgen Inc. | A+ | $224.2B | $414.61 | 25.75 | $38.1B | 23.0% |
| GILD | GILEAD SCIENCES, INC. | A | $187.1B | $150.93 | — | $30.5B | -10.6% |
| NVO | NOVO NORDISK A/S | C+ | $172.6B | $38.80 | 11.07 | $50.1B | 35.3% |
| PFE | PFIZER INC | B | $163.4B | $28.67 | 37.72 | $63.7B | 6.8% |
| BMY | BRISTOL-MYERS SQUIBB COMPANY | B+ | $128.4B | $62.86 | 13.85 | $49.2B | 18.9% |
| GSK | GSK plc | A+ | $106.2B | $49.24 | 13.14 | $44.1B | 17.5% |
| SNY | Sanofi | B | $50.1B | $41.11 | 8.83 | $54B | 16.7% |
| BIIB | BIOGEN INC. | B+ | $33.6B | $227.60 | 24.47 | $9.9B | 13.8% |
| AMRN | AMARIN CORP PLC\UK | D- | $5.5B | $13.20 | — | $186.2M | -14.6% |
| GRFS | Grifols SA | A | $5B | $7.35 | 27.67 | $8.7B | 5.3% |
| OGN | Organon & Co. | C | $3.6B | $13.73 | 17.60 | $6.1B | 3.4% |
| NSRX | Nasus Pharma Ltd | F- | $31.4M | $3.48 | — | $1.2B | -0.5% |
| MIRA | MIRA Pharmaceuticals, Inc. | not rated | $16.2M | $0.90 | — | — | — |
| MDCX | MEDICUS PHARMA LTD. | not rated | $9.6M | $0.15 | — | — | — |
| SCLX | Scilex Holding Company | C | $33.7K | $4.89 | — | $31.6M | -1,469.8% |
Fundamentals from SEC filings, prices from the last market-data pass. Sort by any column; companies with no figure sort last either way.
Sorted by market cap, largest first; click any column to re-sort. Companies with no figure sort last either way, because a missing P/E means unprofitable rather than cheap. Nothing here is a recommendation.